Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies

NCT06703892 is registered in ClinicalTrials.gov with GenomeFrontier Therapeutics TW Co., Ltd. as lead sponsor.

NCT NCT06703892
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06703892 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Randomized, Phase I, Prospective, Dose- Finding Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
Lead sponsor
GenomeFrontier Therapeutics TW Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
June 9, 2025
Completion date
December 31, 2027
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma refractory, diffuse large b cell lymphoma relapsed, follicular lymphoma ( fl), high-grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma-recurrent, primary mediastinal large b-cell lymphoma-refractory